Očkování proti virovým hepatitidám A a B u osob starších 40 let: Srovnání tří vakcín a posouzení působení ovlivňujících faktorů

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F06%3A00001467" target="_blank" >RIV/60162694:G44__/06:00001467 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regiments and effect of influencing factors

Popis výsledku v původním jazyce

Challenged by contrasting data on low immune responses in the elderly with a combined hepatitis A/B vaccine, a randomised, controlled study was conducted to assess the immunogenicity of three hepatitis A and B vaccination regimens (group 1: combined hepatitis A/B vaccine Twinrix# [GSK]; group 2: co-administered hepatitis A vaccine, Havrix# [GSK] + hepatitis B vaccine Engerix#-B [GSK], group 3: co-administered hepatitis A vaccine, Vaqta# [Sanofi-Pasteur MSD] + hepatitis B vaccine HB VAX PRO# [Sanofi-Pasteur MSD]) and the effect of influencing factors in subjects >40 years. On completion of the full vaccination course, anti-HBs seroprotection (SP) rates were 92, 80 and 71% in groups 1, 2 and 3, respectively; anti-HAV seropositivity (S+) rates were 97, 99and 99%, respectively. In group 1, anti-HBs SP rate was non-inferior as well as superior and anti-HAV S+ rate was non-inferior to that in groups 2 and 3. Anti-HBs response was most significantly influenced by the vaccine regimen, followe

Název v anglickém jazyce

Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regiments and effect of influencing factors

Popis výsledku anglicky

Challenged by contrasting data on low immune responses in the elderly with a combined hepatitis A/B vaccine, a randomised, controlled study was conducted to assess the immunogenicity of three hepatitis A and B vaccination regimens (group 1: combined hepatitis A/B vaccine Twinrix# [GSK]; group 2: co-administered hepatitis A vaccine, Havrix# [GSK] + hepatitis B vaccine Engerix#-B [GSK], group 3: co-administered hepatitis A vaccine, Vaqta# [Sanofi-Pasteur MSD] + hepatitis B vaccine HB VAX PRO# [Sanofi-Pasteur MSD]) and the effect of influencing factors in subjects >40 years. On completion of the full vaccination course, anti-HBs seroprotection (SP) rates were 92, 80 and 71% in groups 1, 2 and 3, respectively; anti-HAV seropositivity (S+) rates were 97, 99and 99%, respectively. In group 1, anti-HBs SP rate was non-inferior as well as superior and anti-HAV S+ rate was non-inferior to that in groups 2 and 3. Anti-HBs response was most significantly influenced by the vaccine regimen, followe

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccine

ISSN

0264-410X

e-ISSN

—

Svazek periodika

24

Číslo periodika v rámci svazku

26

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

5509-5515

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—